GSK 2334470 manufacturers
- GSK2334470
-
- $48.00
-
2026-06-02
- CAS:1227911-45-6
- Purity: 99.57%
- Supply Ability: 10g
|
| | GSK 2334470 Basic information |
| Product Name: | GSK 2334470 | | Synonyms: | GSK 2334470;1S,4R)-3-(6-(3-aMino-1H-indazol-6-yl)-2-(MethylaMino)pyriMidin-4-yl)-N-cyclohexyl-4-MethylcyclohexanecarboxaMide;(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide;3-Piperidinecarboxamide, 1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-, (3S,6R)-;(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide GSK 2334470;GSK2334470;GSK 2334470;GSK-2334470;((3S,6R)-1-(6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidin-3-yl)(piperidin-1-yl)methanone;1S,4R)-3-(6-(3-AMINO-1H-INDAZOL-6-YL)-2-(METHYLAMINO)PYRIMIDIN-4-YL)-N-CYCLOHEXYL-4-METHYLCYCLOHEXAN | | CAS: | 1227911-45-6 | | MF: | C25H34N8O | | MW: | 462.59 | | EINECS: | | | Product Categories: | Inhibitors;Akt;mTOR;PI3K;PI3K/Akt/mTOR;API | | Mol File: | 1227911-45-6.mol |  |
| | GSK 2334470 Chemical Properties |
| density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ≥10mg/mL | | form | powder | | pka | 12.84±0.40(Predicted) | | color | white to light brown | | Stability: | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. | | InChIKey | QLPHOXTXAKOFMU-WBVHZDCISA-N | | SMILES | N1(C2C=C(C3=CC4=C(C=C3)C(N)=NN4)N=C(NC)N=2)[C@H](C)CC[C@H](C(NC2CCCCC2)=O)C1 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | GSK 2334470 Usage And Synthesis |
| Description | GSK2334470 (1227911-45-6)is a potent (IC50= 10 nM) and selective inhibitor of 3-Phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates and activates a group of protein kinases in the AGC/PKG/PKC family.1It is more effective at inhibiting PDK1 substrates that are activated in the cytosol rather than at the plasma membrane.1GSK2334470 delayed melanogenesis and metastasis in Braf(V600E)::Pten(-/-)mice.2It also displays antitumor activity against multiple myeloma synergistically with mTORC1/2 inhibitor PP2423and proteasome inhibitor MG-1324. | | Uses | GSK2334470 has been used as an inhibitor of 3-phosphoinositide dependent protein kinase-1 (PDK-1) in:
- Treg cells, to identify regulators of interleukin 2 (IL-2)– signal transducer and activator of transcription 5 (STAT5) signaling
- glycodelin-transfected HEC-1B human endometrial adenocarcinoma cells.
- HeLa and Hs578T cells to test its effect on formylglycinamidine ribonucleotide synthase(FGAMS) assembly
| | Definition | ChEBI: (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide is a member of indazoles. | | Biochem/physiol Actions | GSK2334470 (GSK-470) mediates cell cycle arrest. It also inhibits cellular proliferation and induces apoptosis in cancer cells. | | storage | Store at +4°C | | References | [1] AYAZ NAJAFOV. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.[J]. Biochemical Journal, 2011, 433 2: 357-369. DOI:10.1042/bj20101732
[2] M SCORTEGAGNA. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma[J]. Oncogene, 2013, 33 34: 4330-4339. DOI:10.1038/onc.2013.383
[3] CHUNMEI YANG. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.[J]. Oncotarget, 2017: 39185-39197. DOI:10.18632/oncotarget.16642
[4] JIN ZHANG. PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.[J]. Oncology reports, 2018, 39 6: 2951-2959. DOI:10.3892/or.2018.6369 |
| | GSK 2334470 Preparation Products And Raw materials |
|